GLP-1 Therapies
60 articles on GLP-1 Therapies, researched and written by the Shotlee Editorial Team from primary sources.
Samsung Biologics Acquires PolyPeptide for $1.8 Billion to Expand Peptide Therapeutics
Samsung Biologics has announced a major acquisition of PolyPeptide Group AG for $1.8 billion, marking a strategic expansion into the rapidly growing peptide therapeutics market, particularly for GLP-1 drugs.
8 min read
New “Trojan Horse” Drug Supercharges Weight Loss in Early Trials
A new hybrid molecule designed by Helmholtz Munich researchers acts as a Trojan horse to deliver metabolic compounds directly into cells, showing superior weight loss in mice compared to standard treatments.
8 min read
GP's Verdict on GLP-1 Tablet Rollout: A Damp Squib?
A UK GP shares his observations on the limited uptake of new GLP-1 weight loss tablets, suggesting patient familiarity with injections and daily dosing challenges may be factors.
8 min read
AI Helps Stanford Scientists Discover Natural Ozempic Without the Usual Side Effects
Stanford Medicine researchers have identified a naturally occurring molecule that may suppress appetite and reduce body weight in a way that resembles semaglutide, the active ingredient in Ozempic.
8 min read
China Adds Second GLP-1 Diabetes Drug to Essential Medicine List
China includes injectable semaglutide on its National Essential Drug List, improving access for diabetes patients while excluding obesity indications from the policy.
7 min read
Which GLP-1 Works Best? New Meta-Study Puts Medications Head-to-Head
A comprehensive meta-analysis from the University of Georgia compares three major GLP-1 medications. Discover which drug offers the highest weight loss efficacy and what the data means for patients.
8 min read
Dr. Reddy's Generic Ozempic Supplies Delayed on API Issue
Dr. Reddy's Laboratories has paused commercial production of generic semaglutide following quality concerns with the active ingredient. Here is what patients need to know about the delay and what it means for access to GLP-1 therapy.
8 min read
Managing Ozempic and Wegovy Weight Loss Side Effects: Nausea and Beyond
New research is shedding light on how GLP-1 medications, including popular drugs like Ozempic and Wegovy, influence brain pathways that control nausea, thirst, and reward-driven behaviors. This article delves into these findings and discusses potential strategies for managing common side effects.
7 min read
Novo Nordisk's Semaglutide Implant Could Replace Ozempic Injections
Novo Nordisk and Vivani Medical are developing a semaglutide implant that could eliminate the need for weekly injections. Here is everything to know about the technology.
6 min read
Eli Lilly's Foundayo: A New Daily Pill Outperforming Oral Semaglutide
A groundbreaking Phase 3 trial reveals that Eli Lilly's new daily oral medication, orforglipron (Foundayo), demonstrates superior efficacy in lowering blood sugar and promoting weight loss compared to existing oral semaglutide treatments for individuals with Type 2 diabetes. This development marks a significant step forward in non-injectable peptide therapies for metabolic health.
6 min read
Beyond the Pen: Navigating Weight Loss & Societal Pressures with GLP-1s
Discover how GLP-1 medications are transforming lives, offering significant weight loss and improved self-esteem. This article delves into the personal victories and the broader societal implications, including the persistent pressures on women's bodies.
8 min read
Semaglutide Supply Chain Halted: What Dr. Reddy's API Issue Means for You
Dr. Reddy's Laboratories has paused semaglutide shipments due to active ingredient quality concerns. Here is a deep dive into the impact on the GLP-1 market and patient care.
7 min read
Medicare's $50 GLP-1 Weight Loss Drug Trial: Who Qualifies?
For many older Americans, the high cost of GLP-1 weight loss medications has been a significant barrier. Now, a new Medicare trial offers a lifeline, potentially making these life-changing drugs accessible for just $50 a month. This article breaks down what you need to know about the Medicare GLP-1 Bridge program, including who qualifies, which medications are covered, and the program's future.
8 min read
Navigating Medicare's New Path for GLP-1 Weight Loss Coverage
For years, Medicare coverage for GLP-1 medications like Ozempic and Wegovy was strictly limited to diabetes management. A significant shift is underway, however, as a new 'Bridge' program opens doors for weight loss coverage, albeit with specific requirements and nuances that patients must navigate.
6 min read
Mounjaro Access Expands: Northern Ireland Launches New Weight Loss Service
Northern Ireland is set to launch a £5 million Regional Obesity Management Service, improving access to Mounjaro and lifestyle support for adults struggling with obesity.
8 min read
Ozempic, Wegovy & Mounjaro: How GLP-1s Are Reshaping the Diet Industry
The landscape of weight loss and diet trends is undergoing a seismic shift, largely driven by the widespread adoption of GLP-1 receptor agonists. From Ozempic to Wegovy and Mounjaro, these medications are not just changing how individuals manage their weight but are fundamentally altering the food industry and the very concept of dieting.
7 min read
Wegovy for Children: Safety Concerns, Obesity Trends, and Expert Advice
An in-depth look at the controversial use of GLP-1 medications in pediatric patients, childhood obesity statistics, and long-term safety concerns highlighted by medical experts.
8 min read
Ozempic, Wegovy, Mounjaro: Your Health Journey & What to Track
The rise of GLP-1 medications like Ozempic, Wegovy, and Mounjaro has revolutionized weight management and metabolic health for millions. But beyond the prescription, embarking on this journey requires mindful tracking of your progress, symptoms, and overall well-being. This guide explores what you should be paying attention to, offering practical insights for both patients and the natural health industry.
7 min read
Beyond Weight Loss: GLP-1 Drugs and Unexpected Changes to Taste and Smell
The revolutionary GLP-1 medications, celebrated for their efficacy in diabetes and weight management, are now being scrutinized for a less-discussed side effect: alterations in our senses of smell and taste. A recent study suggests a tangible link between these peptide therapies and sensory disturbances.
6 min read
Oral Wegovy in the UK: A New Era for Weight Management
Novo Nordisk's groundbreaking approval of an oral GLP-1 for weight management in the UK marks a significant shift, promising wider accessibility and influencing consumer markets.
6 min read
Beyond the Hype: Navigating GLP-1s for Sustainable Health
As demand for GLP-1 medications soars, healthcare professionals emphasize a balanced, comprehensive approach to weight management and chronic disease treatment, focusing on sustainability and patient well-being.
7 min read
Beyond the Headlines: Unpacking the Real GLP-1 Weight Loss Race
The booming GLP-1 market for weight loss is often simplified by headline prescription numbers. This article delves deeper, examining the complex factors influencing the success of drugs like Wegovy, Zepbound, and Mounjaro, and what they mean for patients and the industry.
8 min read
Ozempic Alternative Found: Stanford’s BRP Peptide Breakthrough
A new study reveals BRP, a natural peptide, may offer the benefits of Ozempic without common side effects.
7 min read
Ozempic and Testosterone: Does Weight Loss Drive Sperm Quality Gains?
A comprehensive review of clinical trials suggests that GLP-1 medications may offer reproductive benefits for men with obesity-related low testosterone, potentially surpassing traditional hormone replacement therapies.
7 min read
Ozempic and Male Fertility: Can Semaglutide Boost Sperm Quality?
Emerging research indicates that GLP-1 medications, including Ozempic and Mounjaro, may offer unexpected benefits for male reproductive health by addressing underlying metabolic issues.
7 min read
Oral Wegovy's Record-Breaking Launch: The New Era of Needle-Free Weight Loss
Novo Nordisk's Wegovy oral formulation has achieved unprecedented prescription rates, marking a pivotal shift in obesity care and intensifying competition with Eli Lilly.
8 min read
Serena Williams Champions GLP-1s: Ads Air Amidst Tennis Comeback
Tennis legend Serena Williams is making waves both on and off the court. As she returns to professional tennis, advertisements featuring her advocacy for GLP-1 medications are set to air, highlighting a significant cultural moment for weight management therapies.
6 min read
Beyond GLP-1s: Unlocking Better Diabetes Control with Korlym
For individuals struggling with difficult-to-control type 2 diabetes and weight management, even powerful GLP-1 medications might not be enough. New research highlights the significant role of hypercortisolism and the promising potential of Korlym in optimizing treatment outcomes.
6 min read
Beyond Ozempic: New Muscle-Burning Pill Reshaping Diabetes Care
A new experimental medication from Karolinska Institute targets muscle metabolism rather than appetite, offering a potential alternative to Ozempic and Wegovy with fewer side effects.
6 min read
Ozempic Muscle Loss: How a New Compound Preserves Strength
New research from Stanford Medicine reveals a potential solution to the muscle loss associated with GLP-1 medications like Ozempic and Wegovy, offering hope for stronger, healthier weight loss.
8 min read
Wegovy, Mounjaro & Your Libido: How GLP-1s Reshape Desire
GLP-1 medications have transformed weight management and diabetes care, but their effects extend beyond the scale. Many users report surprising changes to their libido and sexual function. This article delves into why these powerful drugs can either boost or dampen your sex drive, offering insights from leading medical experts.
9 min read
Beyond Ozempic: A New Pill Targets Fat Metabolism Without Appetite Loss
A groundbreaking pill developed by researchers at Karolinska Institutet and Stockholm University offers a new avenue for treating type 2 diabetes and obesity. Unlike injectable GLP-1 agonists, this oral medication targets muscle metabolism to enhance fat burning and improve blood sugar control, aiming to circumvent common side effects.
7 min read
Ozempic Weight Loss: Why Your Body Needs One More Key Step
Ozempic is a household name, but experts warn it isn't a magic bullet. Dr. Shilpa Verma discusses the essential lifestyle component required for sustainable weight loss.
6 min read
Wegovy Pill Arrives: A New Era for Oral Weight Management in the UAE
Novo Nordisk's revolutionary Wegovy pill (oral semaglutide) is set to transform weight management in the UAE. Discover the details of its early access launch, clinical benefits, and how it integrates into advanced care pathways.
7 min read
Beyond Weight Loss: The Expanding Horizon of GLP-1 Therapies
GLP-1 agonists, famously known for Ozempic and Wegovy, are making waves beyond their initial indications. While weight loss and diabetes management remain key, researchers are uncovering a broader therapeutic potential for these powerful peptide therapies.
8 min read
GLP-1 Therapies: Australia's New Blueprint for Obesity and Heart Health
Australia has released a groundbreaking clinical consensus statement on obesity and cardiovascular disease (CVD), marking a pivotal moment in medical practice. This new guidance places GLP-1 receptor agonists—a class of medications including semaglutide and tirzepatide—at the forefront of treatment strategies, offering clinicians a clear, practical pathway for improving patient outcomes.
6 min read
Beyond the Injection: GLP-1s, Diet, and the Future of Weight Management
GLP-1 receptor agonists have revolutionized obesity and diabetes management, offering unprecedented appetite control. However, as adoption surges, especially in markets like India, medical experts emphasize that these powerful tools must be integrated with fundamental lifestyle changes and supportive public health infrastructure to ensure lasting success.
6 min read
Ozempic & Wegovy: Unlocking the Brain's Fading Appetite Signals
A groundbreaking study reveals that the effectiveness of semaglutide, the active ingredient in popular weight loss medications like Ozempic and Wegovy, may be linked to the duration and intensity of chemical signals within specific brain cells. This research sheds light on why weight loss can plateau and offers clues for developing more sustained and effective future therapies.
6 min read
Retatrutide's Rapid Weight Loss: Balancing Benefits and Risks
New-generation GLP-1 drugs like retatrutide promise unprecedented weight loss, but what are the implications for your body's composition and overall health? This article delves into the science, risks, and strategies for navigating rapid weight reduction.
8 min read
Semaglutide Plateaus: New Brain Discovery Could Boost Weight Loss Results
New research from the NIH reveals how semaglutide signaling in the brain affects weight loss plateaus, offering hope for improved efficacy and dosing strategies.
7 min read
Beyond the Injection: The Future of GLP-1 Therapies
GLP-1 receptor agonists have revolutionized weight loss and diabetes management, but researchers are continuously seeking ways to enhance their delivery. This article delves into cutting-edge advancements, from nanocarriers to microneedles, aiming to make these powerful therapies more effective, tolerable, and convenient.
7 min read
Mounjaro vs. Wegovy: Decoding the Global Shift in Weight Loss Therapy
The competition between Eli Lilly and Novo Nordisk is reshaping obesity treatment. Learn the clinical differences between Mounjaro and Wegovy, and why international market dynamics matter for patient access.
7 min read
Beyond Glucose: GLP-1 Therapies Reshape Metabolic Care
The GLP-1 receptor agonist market is experiencing explosive growth, transforming from a diabetes-focused treatment to a cornerstone of comprehensive metabolic care. Discover the key drivers, leading molecules like semaglutide and tirzepatide, and the future outlook.
10 min read
Ozempic, Mounjaro & More: AI Uncovers Hidden GLP-1 Side Effects
Popular GLP-1 medications such as semaglutide and tirzepatide are revolutionizing weight loss and diabetes management. A groundbreaking study using AI to analyze over 400,000 Reddit posts has shed light on potential side effects that may not be fully captured in traditional clinical trials, offering valuable insights for patients and healthcare providers.
7 min read
Ozempic, Wegovy, Mounjaro: The GLP-1 Revolution Reshaping Health
The GLP-1 analogue market is experiencing unprecedented growth, transforming from diabetes treatments to comprehensive cardiometabolic solutions. Discover the key drivers, leading medications, and future innovations shaping this dynamic field.
9 min read
Retatrutide Breakthrough: Can This Molecule Rival Gastric Bypass Surgery?
New data suggests Eli Lilly's retatrutide could deliver up to 28% weight loss, potentially rivaling bariatric surgery. Learn about efficacy and safety.
8 min read
Beyond the Hype: How GLP-1s Like Wegovy Are Reshaping Retail Spending
The growing popularity of GLP-1 medications, including Wegovy, is having a notable impact on retail spending, particularly in the pharmaceutical sector. This article delves into the economic implications and what it means for consumers and businesses.
6 min read
Ozempic Price Cut: Generic Semaglutide Arrives in Canadian Pharmacies
Two generic versions of Ozempic have arrived in Canadian pharmacies, offering diabetes and weight loss patients significant cost savings compared to the brand-name medication.
7 min read
Retatrutide Trials: Why Extreme Weight Loss Isn't Always Safe
Clinical trials for the triple-agonist Retatrutide show promising weight loss, but 11% of high-dose participants dropped out due to side effects.
7 min read
GLP-1s, Hormones, and Weight Loss: What Women Need to Know
Many women starting GLP-1 therapies experience significant weight loss, only to find their menopausal symptoms—like hot flashes and sleep issues—intensify. This phenomenon is often overlooked because rapid fat loss directly interacts with the body's declining estrogen production, creating a complex hormonal shift that many prescribers are not trained to address.
6 min read
GLP-1 Medications and Supplement Needs: What You Should Know
As GLP-1 medications gain popularity for weight loss and diabetes management, understanding their impact on nutrient absorption is crucial. This article explores the link between these powerful drugs and the rising demand for supplements, offering insights from medical professionals and research.
6 min read
Retatrutide: Eli Lilly's New Drug Challenges Ozempic in Weight Loss
Eli Lilly's experimental drug Retatrutide is making waves with unprecedented weight loss results in clinical trials, potentially setting a new benchmark in obesity treatment. This comprehensive look examines its efficacy, mechanism, and comparison to existing GLP-1 and GIP agonists.
8 min read
GLP-1 Drugs: A New Frontier in Addiction Treatment?
Could the same medications revolutionizing weight loss and diabetes management also hold the key to treating addiction? Emerging research suggests GLP-1 receptor agonists may play a significant role.
8 min read
Michelle Obama's Weight: Addressing Speculation and GLP-1 Rumors
Recent public appearances by Michelle Obama have sparked widespread discussion about her appearance and weight. This article delves into the speculation, explores the role of GLP-1 medications in weight management, and discusses the broader implications of public observation on health and wellness.
6 min read
The Next Wave of Weight Loss: Understanding Oral GLP-1 Therapy
The landscape of chronic weight management is rapidly evolving beyond injectable GLP-1 medications. New research, including trials for the oral, non-peptide drug orforglipron, suggests a future where highly effective weight loss treatment is as simple as taking a daily pill, potentially overcoming barriers of cost and injection fatigue.
6 min read
Peptide Therapy Science: Weighing Benefits and Risks
Peptides offer targeted health benefits, from weight loss to injury healing, but safety varies significantly. Explore the science, risks, and medical guidance required.
7 min read
Understanding Peptides: Beyond the Hype of GLP-1s and Skincare
Peptides are powerful signaling molecules, but they are not a universal cure-all. This deep dive clarifies the function of GLP-1 agonists, cosmetic peptides, and the critical importance of medical guidance when considering peptide therapies for weight management or anti-aging.
6 min read
GLP-1 Weight Loss Drugs: Eli Lilly's Next-Gen Therapies vs. Novo Nordisk
The race for dominance in the lucrative weight loss drug market is intensifying. While Novo Nordisk's Wegovy has been a pioneer, Eli Lilly is rapidly advancing its pipeline with next-generation therapies poised to challenge the status quo. This article delves into the science, clinical data, and market implications of these groundbreaking treatments.
6 min read
Reclaiming Your Health: Beyond Weight Loss with GLP-1 Therapies
Explore the profound impact of GLP-1 medications, like semaglutide and tirzepatide, on not just weight management but also on reclaiming one's identity and overall health. Learn how these therapies can be a catalyst for significant life changes, as illustrated by personal journeys.
10 min read
Generic Semaglutide Launches in Canada: What Patients Need to Know
The Canadian market sees the arrival of a generic semaglutide injection, a significant development for individuals managing type 2 diabetes and seeking weight loss solutions. This launch by Dr. Reddy's Laboratories marks a new era of accessibility for this popular GLP-1 therapy.
7 min read